Abarelix
FDA-approved product (powder, intramuscular), marketed as Plenaxis.
- Registered studies
- 5
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Neoplasm
Indications ChEMBL records as approved, from FDA and DailyMed labels.
- WHO therapeutic group
- Other hormone antagonists and related agents
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA67.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli53.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae34.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis62.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
5registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Abarelix with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- DichlorphenamideExisting use: Glaucoma73.9% AI-predicted activityagainst M. tuberculosisLab records exist2 registered studies
- Tamsulosin HydrochlorideExisting use: Benign prostatic hyperplasia, Prostate carcinoma73.2% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Thiethylperazine MalateExisting use: Allergic disease71.8% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- SaquinavirExisting use: HIV infection, HIV-1 infection, Viral disease71.5% AI-predicted activityagainst M. tuberculosis50+ registered studies
- AvacopanExisting use: Anti-neutrophil antibody associated vasculitis, Anti-neutrophil cytoplasmic antibody-associated vasculitis, Granulomatosis with Polyangiitis and 1 more71.3% AI-predicted activityagainst M. tuberculosis26 registered studies
- Lasmiditan SuccinateExisting use: Migraine disorder71.0% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- SotorasibExisting use: Neoplasm, Non-small cell lung carcinoma71.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Vinblastine SulfateExisting use: Classic Hodgkin lymphoma, Fungal infectious disease, Hodgkins lymphoma and 3 more70.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Haloperidol DecanoateExisting use: Conduct disorder, Mental or behavioural disorder, Psychosis and 4 more70.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- HydrochlorothiazideExisting use: Angina pectoris, Cardiovascular disease, Chronic kidney disease and 9 more70.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- TolvaptanExisting use: Autosomal dominant polycystic kidney disease, Cardiovascular disease, Congestive heart failure and 4 more70.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Larotrectinib SulfateExisting use: Abdominal Neoplasms, Cancer, Metastasis and 1 more69.2% AI-predicted activityagainst M. tuberculosis5 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
NCT06379217 · start 2024-07-29
Registered record
- Registry ID
- NCT06379217
- Conditions
- Metastatic Neuroendocrine Prostate Cancer
- Interventions
- [68Ga]Ga-PSMA-11; [68Ga]GA-DOTA-TATE; [68Ga]Ga-NeoB; [177Lu]Lu-PSMA-617; [177Lu]Lu-DOTA-TATE; [177Lu]Lu-NeoB; L-Lysine HCl-L-Arginine HCl, 2.5 %,; Gonadotropin-releasing hormone (GnRH) analogues; GnRH antagonists; Antiemetics & antinauseants; Metoclopramide
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Active not recruiting
- Start
- 2024-07-29
- Completion
- 2026-08-31
- Enrolment
- 31
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMetastatic Neuroendocrine Prostate CancerIntervention[68Ga]Ga-PSMA-11; [68Ga]GA-DOTA-TATE; [68Ga]Ga-NeoB; [177Lu]Lu-PSMA-617 +7 morePhasePhase 1Registry statusActive not recruitingDiagnosis of Pelvic Endometriosis in MRI
NCT06157528 · start 2023-12-20
Registered record
- Registry ID
- NCT06157528
- Conditions
- Endometriosis
- Interventions
- Magnetic resonance imaging
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Not yet recruiting
- Start
- 2023-12-20
- Completion
- 2029-12
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEndometriosisInterventionMagnetic resonance imagingPhaseNot applicableRegistry statusNot yet recruitingThe Plenaxis® Experience Study
NCT00103623 · start 2004-06
Registered record
- Registry ID
- NCT00103623
- Conditions
- Prostate Cancer
- Interventions
- Plenaxis
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Suspended
- Start
- 2004-06
- Completion
- 2008-12
- Enrolment
- 2,000
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate CancerInterventionPlenaxisPhasePhase 4Registry statusSuspendedStudy of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy
NCT00100243 · start 2004-05
Registered record
- Registry ID
- NCT00100243
- Conditions
- Prostate Cancer
- Interventions
- Plenaxis
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2004-05
- Completion
- 2005-09
- Enrolment
- 22
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate CancerInterventionPlenaxisPhasePhase 2Registry statusCompletedAbarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer
NCT00841113 · start 1999-01
Registered record
- Registry ID
- NCT00841113
- Conditions
- Prostate Cancer
- Interventions
- Abarelix; Goserelin plus Bicalutamide
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 1999-01
- Completion
- 2003-02
- Enrolment
- 177
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate CancerInterventionAbarelix; Goserelin plus BicalutamidePhasePhase 3Registry statusCompleted